Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories View More Recent Stories
-
Theravance Biopharma (TBPH) Appoints Jim Kelly to its Board
-
Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors
-
Form SC 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Form PREC14A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G Forest Road Acquisition Filed by: Farallon Capital Partners, L.P.
-
Exelixis Reiterates Commitment to Shareholder Value Creation
-
Form DFAN14A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Farallon Issues Letter to Exelixis (EXEL) Board of Directors Outlining Case for Change
-
Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change
-
AUNA ANNOUNCES SIGNING OF US$505 MILLION FINANCING
-
Form SC 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
The $15 billion scramble for Japan's Toshiba went from bang to whimper
-
Form SC 13D Cazoo Group Ltd Filed by: Farallon Capital Partners, L.P.
-
Form SC 13D EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13D/A Atento S.A. Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form D/A Farallon Capital Partner
-
Form D/A FARALLON CAPITAL OFFSHOR
-
Form D/A Farallon Capital Institu
-
Form D/A Farallon Capital (AM)
-
Form SC 13G AVROBIO, Inc. Filed by: Farallon Capital Partners, L.P.
-
'Big Short' manager Burry, Farallon among hedge funds making bets on China
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
-
Form 13F-NT Farallon Capital Europe For: Dec 31
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Dec 31
-
Form SC 13G/A Shelter Acquisition Corp Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Protagonist Therapeutics Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Swiftmerge Acquisition Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Clever Leaves Holdings Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Metals Acquisition Corp Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A SDCL EDGE Acquisition Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A CLARIVATE Plc Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Better Therapeutics, Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A AMYRIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Marblegate Acquisition Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A SEP Acquisition Corp. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Inflection Point Acquisi Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A ENANTA PHARMACEUTICALS Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Savara Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Longboard Pharmaceutical Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Aramark Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Imago BioSciences, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Generation Bio Co. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Big Sky Growth Partners, Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Disruptive Acquisition Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Berenson Acquisition Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A ARYA Sciences Acquisitio Filed by: Farallon Capital Partners, L.P.
-
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline

